Recent advances in feeding suppressing agents: Potential therapeutic strategy for the treatment of obesity

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 11, 2001, Pages 1677-1692

  Chaki, S ^a   Nakazato, A ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 HT2C receptor agonists; Anti obesity agents; CCK receptor agonists; CRF receptor agonists; Galanin receptor antagonists; Leptin; MC4 receptor agonists; MCH receptor antagonists; Neuropeptide Y receptor antagonists; Orexin receptor antagonists

Indexed keywords

AMINE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; BENZENESULFONAMIDE DERIVATIVE; CGP 71683 A; DEXFENFLURAMINE; DIHYDROPYRIDINE DERIVATIVE; FENFLURAMINE; GALANIN; INDOLE DERIVATIVE; L 152804; LEPTIN; MELANOCORTIN RECEPTOR; MONOAMINE; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROTRANSMITTER; PEPTIDE; PIPERAZINE DERIVATIVE; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRAZOLOTRIAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SEROTONIN 2C AGONIST; SEROTONIN ANTAGONIST; SULFONAMIDE; SULFONYLQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APPETITE; BRAIN; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INDUSTRY; DRUG STRUCTURE; DRUG SYNTHESIS; ENERGY BALANCE; ENERGY EXPENDITURE; FEEDING BEHAVIOR; HEALTH STATUS; HUMAN; HUMAN CELL; HYPOTHALAMUS; MEDICAL RESEARCH; MODULATION; MOLECULE; NONHUMAN; OBESITY; PATENT; PREVALENCE; RAT; REVIEW; TREATMENT PLANNING;

EID: 0034764137     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.11.1677     Document Type: Review

References (117)

1. Central nervous system control of food intake
2. Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice
3. Leptin receptor missense mutation in the fatty Zucker rat
4. Positional cloning of the mouse obese gene and its human homologue
5. Unravelling the central nervous system pathways underlying responses to leptin
6. Effects of recombinant leptin therapy in a child with congenital leptin deficiency
7. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial
8. Weekly subcutaneous pegylated recombinant native human leptin (PEGOB) administration in obese men
9. Strategies and potential molecular targets for obesity treatment
10. Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism
11. 1 receptor mediating this peptide's effect
12. Neuropeptide Y and pancreatic polypeptide stimulates feeding behavior in rats
13. Neuropeptide Y stimulates feeding, but inhibits sexual behavior in rats
14. Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppress feeding behavior and insulin secretion
15. Evidence that neuropeptide Y is a physiological signal for normal food intake
16. The role of neuropeptide Y in the antiobesity action of the obese gene product
17. Increased neuropeptide Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse
18. Attenuation of the obesity syndromes of ob/ob mice by the loss of neuropeptide Y
19. Y-receptor subtypes-how many more?
20. A receptor subtype involved in neuropeptide-Y-induced food intake
21. 1-selective antagonist BIBP3226
22. Subtype selectivity of the novel nonpeptide neuropeptide YY1 receptor antagonist BIBO3304 and its effect on feeding in rodents
23. Apparent affinity and potency of BIBP3226, a non-peptide neuropeptide Y receptor antagonist, on purported neuropeptide Y Y1, Y2 and Y3 receptor
24. Neuropeptide Y induced feeding in the rat is mediated by a novel receptor
25. Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists
26. 1 receptor antagonists
27. Structure-activity relationship of a series of benzothiophene-derived NPY Y1 antagonists: Optimization of the C-2 side chain
28. 1 receptor antagonists
29. The novel neuropeptide Y Y(1) receptor antagonist J-104870: A potent feeding suppressant with oral bioavailability
30. 1 receptors
31. 1 receptor antagonist
32. 1 antagonists, J-115814
33. Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazol neuropeptide Y Y5 receptor antagonists
34. Design and biological activities of L-163,191 (MK-0677): A potent, orally active growth hormone secretagogue
35. 5 receptor antagonist
36. 5 receptor antagonists
37. Galanin-a novel biologically active peptide from porcine intestine
38. Autoradiographic distribution of 125I-galanin binding sites in the rat central nervous system
39. Galanin: Stimulation of feeding induced by medial hypothalamic injection
40. Effects of PVN galanin on macronutrient selection
41. Galanin-containing neurons in the paraventricular nucleus: A neurochemical marker for fat ingestion and body weight gain
42. Impact of a galanin antagonist on exogenous galanin and natural patterns of fat ingestion
43. Galanin regulates prolactin release and lactotroph proliferation
44. Molecular cloning of a functional human galanin receptor
45. Cloning, pharmacological characterization, and anatomical distribution of a rat cDNA encoding for a galanin receptor
46. Molecular cloning and characterization of a new receptor for galanin
47. Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover
48. Molecular cloning and pharmacological characterization of a new galanin receptor subtype
49. Cloning and expressional characterization of a novel galanin receptor
50. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G-protein coupled receptors that regulate feeding behaviour
51. The novel brain neuropeptide orexin-A modulates the sleep-wake cycle of rats
52. Food intake elicited by central administration of orexins: Identification of hypothalamic sites of action
53. SB-334867-A: The first selective orexin-1 receptor antagonist
54. SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats
55. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation
56. A role for melanin-concentrating hormone in the central regulation of feeding behavior
57. Mice lacking melanin-concentrating hormone are hypophagic and lean
58. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance
59. Identification of melanin concentrating hormone (MCH) as the natural ligand for orphan somatostatin-like receptor 1 (SLC-1)
60. Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1
61. The receptor for the orexigenic peptide melanin-concentrating hormone is G-protein-coupled receptor
62. Molecular characterization of the melanin-concentrating-hormone receptor
63. Identification and characterization of a melanin-concentrating hormone receptor
64. 2, a novel human MCH receptor
65. Cloning of a novel G protein-coupled receptor, SLT, a subtype of the melanin-concentrating hormone receptor
66. Identification and characterization of a second melanin-concentrating hormone receptor. MCH-2R
67. Ghrelin induces adiposity in rodents
68. Serum immunoreactive leptin concentration in normal-weight and obese humans
69. Cerebrospinal fluid leptin level: Relationship to plasma levels and adiposity in humans
70. Leptin and the regulation of body weight in mammals
71. Feeding inhibition by neuropeptide Y
72. Molecular cloning of a novel melanocortin receptor
73. Molecular cloning, expression, and gene localization of a forth melanocortin receptor
74. Identification of a receptor for γ melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system
75. Targeted disruption of the melanocortin-4 receptor results in obesity in mice
76. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome
77. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein
78. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice
79. ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors
80. AgRP(83-132) acts as inverse agonist on the human-melanocortin-4 receptor
81. 5 neuropeptide Y receptor in feeding and obesity
82. Corticotropin-releasing factor and behavior
83. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims
84. Corticotropin-releasing factor Type 1 mediates emotional stress induced inhibition of food intake and behavioral changes in rats
85. Corticotropin-Releasing Factor: Basic and clinical studies of a neuropeptide
86. Preoptic are injection of corticotropin-releasing hormone stimulates sympathetic activity
87. Expression cloning of a human corticotropin-releasing factor receptor
88. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from the rat brain
89. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart
90. 2γ receptor
91. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide
92. 1 receptor mRNA expression
93. Displacement of corticotropin releasing factor from its binding protein as possible treatment for Alzheimer's disease
94. Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal
95. Purification and characterization of a new hypothalamic satiety peptide, cocaine and amphetamine regulated transcript (CART), produced in yeast
96. Hypothalamic CART is a new anorectic peptide regulated by leptin
97. Intravenous infusion of bombesin reduces food intake in humans
98. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity
99. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight
100. Cholecystokinin decreases food intake in rats
101. Cholecystokinin decreases food intake in rhesus monkeys
102. Behavioral effects of A71623, a highly selective CCK-A agonist tetrapeptide
103. Blockade of type A, but not type B, CCK receptors postpones satiety in rhesus monkeys
104. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amini substituent
105. Optimization of 3-(1H-indazol-3-ylmethyl)- 1,5-benzodiazepines as potent and orally active CCK-A agonists
106. A role for glucagon-like peptide 1 in the central regulation of feeding
107. Appetite suppression by commonly used drugs depends on 5-HT receptor, but not on 5-HT availability
108. 2C serotonin receptors
109. 2C receptor gene
110. 2C receptors. Synthesis and biological evaluation of substituted 2-(indol-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder
111. 2A receptor: Potential therapeutic applications for epilepsy and obesity
112. 2C receptor agonist and d-fenfluramine on feeding patterns in the rat
113. Lose weight STAT: CNTF tops leptin
114. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y
115. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor
116. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides
117. Serotonin and the biology of feeding